Pan An-Peng, Wen Li-Jin, Shao Xu, Zhou Kai-Jing, Wang Qin-Mei, Qu Jia, Yu A-Yong
The Eye Hospital of Wenzhou Medical University, 270 Xueyuan West Road, Wenzhou, 325000 Zhejiang P. R. China.
Eye Vis (Lond). 2020 Apr 7;7:18. doi: 10.1186/s40662-020-00185-4. eCollection 2020.
To assess the efficacy and safety of a novel ophthalmic viscosurgical device-free (OVD-free) method for posterior chamber phakic intraocular lens (PIOL) implantation in myopic eyes.
In this retrospective cohort study, the medical records of myopic eyes that underwent PIOL (Implantable Collamer Lens, ICL) implantation for myopia correction at the Eye Hospital of Wenzhou Medical University between May 2015 and March 2017 were reviewed. A total of 49 eyes with complete data that met follow up requirements (2 h, 1 day, 1 week, 3 months postoperatively) were recruited. Based on the surgical techniques used, the eyes were divided into the OVD-free method group and the standard method group. The clinical data, including intraocular pressure (IOP), corrected distance visual acuity (CDVA) and spherical equivalent (SE), at each follow-up were collected for comparison. Endothelial cell loss and complications were also investigated.
Twenty-one eyes received the standard method, and 28 eyes received the OVD-free method. A rise in IOP > 22 mmHg at 2 h was noted in 14 eyes (66.7%) in the standard group and none (0%) in the OVD-free group ( < 0.001). The rise in IOP from baseline was significantly higher at 2 h in the standard group (10.5 ± 5.2 mmHg vs. 2.2 ± 3.3 mmHg, difference: 8.3, 95% CI 5.8 to 10.8; < 0.001). There was a significant difference in the time course of LogMAR CDVA changes between the two groups ( = 0.047). The LogMAR CDVA was significantly better in the OVD-free method group compared to the standard group at 1 day (- 0.076, 95% CI - 0.134 to - 0.018; = 0.012), 1 week (- 0.071, 95% CI - 0.135 to - 0.007; = 0.03), but not at 3 months (- 0.046, 95% CI - 0.107 to 0.015; = 0.134). There was no significant difference in the time course of SE changes between the two groups ( = 0.471; = 0.705). In the OVD-free group, mean endothelial cell loss was 4.6% at 3 months (2522 ± 281 vs. 2407 ± 226 cells/mm, difference: -115, 95% CI - 295 to 65; = 0.187). No complications were reported in both groups except for the early IOP elevation in the standard group during the observation period.
The OVD-free method is safe and efficient for ICL implantation. It can be a safer method of ICL implantation compared to the standard method in that it completely eliminates ophthalmic viscoelastic devices-related complications without causing additional complications.
评估一种新型免眼内填充剂(OVD-free)方法用于近视眼后房型有晶状体眼人工晶状体(PIOL)植入的有效性和安全性。
在这项回顾性队列研究中,回顾了2015年5月至2017年3月在温州医科大学眼视光医院接受PIOL(可植入式胶原晶状体,ICL)植入以矫正近视的近视眼的病历。共纳入49只具有完整数据且符合随访要求(术后2小时、1天、1周、3个月)的眼睛。根据所使用的手术技术,将这些眼睛分为免OVD方法组和标准方法组。收集每次随访时的临床数据,包括眼压(IOP)、矫正远视力(CDVA)和等效球镜度(SE),进行比较。还研究了内皮细胞丢失和并发症情况。
21只眼睛接受标准方法,28只眼睛接受免OVD方法。标准组14只眼睛(66.7%)在2小时时眼压升高>22 mmHg,免OVD组无一只眼睛出现这种情况(<0.001)。标准组在2小时时眼压较基线的升高显著更高(10.5±5.2 mmHg对2.2±3.3 mmHg,差值:8.3,95%CI 5.8至10.8;<0.001)。两组之间LogMAR CDVA变化的时间进程存在显著差异(=0.047)。免OVD方法组在1天(-0.076,95%CI -0.134至-0.018;=0.012)、1周(-0.071,95%CI -0.135至-0.007;=0.03)时的LogMAR CDVA显著优于标准组,但在3个月时无差异(-0.046,95%CI -0.107至0.015;=0.134)。两组之间SE变化的时间进程无显著差异(=0.471;=0.705)。在免OVD组,3个月时平均内皮细胞丢失率为4.6%(2522±281对2407±226个细胞/mm,差值:-115,95%CI -295至65;=0.187)。观察期内,除标准组早期眼压升高外,两组均未报告并发症。
免OVD方法用于ICL植入安全有效。与标准方法相比,它可能是一种更安全的ICL植入方法,因为它完全消除了与眼内粘弹性装置相关的并发症,且未引起额外并发症。